BiotechTube
Home/Pipeline/First Biosimilar (unspecified)

First Biosimilar (unspecified)

Not specified

ApprovedActive

Key Facts

Indication
Not specified
Phase
Approved
Status
Active
Company
Zentiva

About Zentiva

Zentiva is a major European generics and biosimilars company with a 530-year heritage, founded in its modern form in 2003. It operates four manufacturing sites, employs over 5,400 people, and markets over 265 product presentations, ensuring supply security for essential medicines. The company is privately held, recently transitioning from ownership by Advent International to GTCR, and is strategically expanding into biosimilars while actively advocating for sustainable pharmaceutical policies in the EU.

View full company profile

Therapeutic Areas

Cardiology and CirculationDiabetesOncologyRespiratoryCNSConsumer Health

Other Not specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved